比阿培南治疗恶性血液病合并感染疗效观察

Efficacy of biapenem treating infection in 134 patients with hematologic malignancies

目的评价比阿培南治疗恶性血液病患者合并中、重度感染时的临床疗效及安全性。方法回顾性分析2011年1月至2012年6月在我科住院的134例恶性血液病患者合并感染后应用比阿培南治疗的疗效。比阿培南用药剂量为0．3g每8小时1次静脉滴注，疗程3—24d。按卫生部颁发的抗菌药物临床研究指导原则判定疗效。结果比阿培南治疗本组恶性血液病合并感染的有效率为78．4％（105／134，痊愈＋显效）；在合并败血症19例中，16例有效；中性粒细胞绝对数在0．5X10’／L以下者，有效率达73．5％（61／83）。不良反应发生率为3．7％（4／134）。结论比阿培南治疗恶性血液病合并感染疗效显著，安全性好。

Objective To investigate the clinical efficacy and tolerance of intravenous biapenem treating infections in 134 patients with hematologic malignancy. Methods The clinical data of 134 cases of biapenem- treated infections in patients with hematologic malignancy were reviewed in department of hematology from January 2011 to June 2012. The dosage of biapenem was O. 3 g qSh for all infections. The treatment duration was 3 to 24 days. The efficacy evaluation was conducted according to the guidelines on clinical trial of antimicrobial agents released by ministry of health. Results Biapenem treatment was effective in 78.4% （105/134） of patients with hematologic malignancy. Biapenem was also effective in 16/19 cases of septicemia. Biapenem was effective in 73.5 % （61/83） of patients whose absolute neutrophils count was lower than 0.5 x 109/L. The incidence of adverse reactions was 3.7% （4/134）. Conclusions Biapenem is high effective and tolerant in treating infections of patients with hematologic malignancy.